Article Text
Abstract
INTRODUCTION
Fabry disease, also known as Anderson–Fabry disease, is an X-linked inborn error of metabolism caused by deficiency of the lysosomal enzyme α-galactosidase A, the gene for which is localized at Xq22. It is the second most common lysosomal storage disorder (after Gaucher disease). Birth frequency estimates range from 1 : 20 000 to 1 : 100 000. As a consequence of the enzyme defect, neutral glycosphingolipids, notably globotriaosylceramide (Gb3), accumulate in many tissues, including the nervous system, vascular endothelium, heart, kidney, eye and gastrointestinal tract.
NON-NEUROLOGICAL MANIFESTATIONS
A characteristic skin rash – angiokeratoma corporis diffusum – is the consequence of ectasia of individual blood vessels, covered by a few layers of skin, which may become hyperkeratotic. The lesions are flat or slightly raised, dark red to blue in colour, and are usually found in the ‘bathing trunks’ area (Fig. 1), though often they are more widely distributed. Telangiectasias may also
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease
- The heart in Anderson-Fabry disease and other lysosomal storage disorders
- Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease
- Central nervous system involvement in Anderson–Fabry disease: a clinical and MRI retrospective study
- Musculoskeletal manifestations of lysosomal storage disorders
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males
- Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy
- Fabry heterozygote mimicking multiple sclerosis
- Prevalence of Anderson–Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson–Fabry Disease Survey
- Screening for Fabry disease in high-risk populations: a systematic review